OBJECTIVES: Determine whether treatment of asthma with drug therapy in adults has changed since the FDA label change in 2010. This label change stipulates ICS/LABA drugs are to be used only if a patient is uncontrolled on a plain ICS, and then for the shortest period possible after achieving control. METHODS: Catalina Health receives data from a nationally representative sample of pharmacy chains, representing approximately 40% of all national retail prescription volume, and comprised of over 130 million unique patients. Data are captured daily from the pharmacies, are fully HIPAA compliant, longitudinal, and not projected. Patient cohorts included patients initiating ICS/LABA therapy as their first controller medication, before and after the label change. Both cohorts were followed for a year to determine if fills of ICS/LABA medication as initial therapy had declined and if days of therapy had shortened. RESULTS: Patient cohort consisted of 7,040 patients who initiated ICS/LABA therapy during November, 2008 and 6,971 patients who initiated ICS/LABA therapy during November, 2011. There was no overlap of patients between the two groups. Cohorts had no prior fills of ICS/LABAs or a plain ICS drug. Patients were between the ages of 12 and 40 to eliminate children and COPD patients. Patients with fills of COPD drugs (anticholinergics or xanthines) were excluded. Patients with only one fill of an ICS/LABA and no fills of an ICS during the year were excluded (pneumonia patients).Comparing the two cohorts, the key findings were Average Days of Therapy on the ICS/LABA declined from 78.8 to 76.6 (p-value=.068). Average fills of an ICS/LABA declined from 2.57 to 2.45 (p-value=.002). CONCLUSIONS: The differences between the cohorts are small, but are statistically significant, indicating the label change is being adopted in the management of asthma patients.